Encompass Health Corporation (EHC) Stock Price & How to Invest

Encompass Health runs inpatient rehabilitation facilities, or IRFs: hospitals that take patients after a stroke, a hip fracture, a brain or spinal cord injury, or major surgery, and put them through intensive physician-supervised therapy before they go home. As of the second quarter of 2026 it operated 176 hospitals across 39 states and Puerto Rico, which makes it the largest operator in the category by a wide margin. Medicare fee-for-service is its dominant payer, and under the IRF prospective payment system it is paid a set amount per discharge based on the patient's condition and complexity, so revenue is essentially discharges multiplied by net revenue per discharge. A portion of its hospitals are structured as joint ventures with acute-care health systems, which brings referral flow and shared construction capital while handing a slice of consolidated profit to noncontrolling interests. The company became a pure-play rehabilitation operator in 2022 when it spun off its home health and hospice arm as Enhabit.

The investment picture is unusually mechanical for a healthcare name. Second-quarter 2026 revenue was about $1.60 billion, up 9.6 percent, with adjusted EBITDA of roughly $348 million and adjusted earnings per share of about $1.55. Discharges rose 5.6 percent while same-store discharges rose 2.8 percent, so a little under half the volume growth came from capacity that did not exist a year ago. Management raised full-year 2026 guidance to $6.41 billion to $6.49 billion of revenue, $1.365 billion to $1.395 billion of adjusted EBITDA, and adjusted EPS of $6.02 to $6.25. At roughly $125 a share and a market capitalization near $12.3 billion, that is about 20 times the midpoint of guided adjusted earnings. What the multiple is really pricing is whether the new-hospital pipeline keeps converting, whether annual Medicare rate updates stay ahead of wage inflation, and how much of the patient pool Medicare Advantage plans redirect to cheaper post-acute settings.

Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. Medicare Advantage penetration is the slower-moving version of the same risk: MA plans authorize fewer IRF days, deny more admissions, and push patients toward skilled nursing or home health at lower rates. The 60 percent rule is a hard operational gate, because a hospital that falls below the compliance threshold is paid under the acute-care system instead, which is materially worse. Wage inflation and any return of contract labor would compress margins quickly given how large salaries and benefits are relative to revenue, and de novo hospitals can be delayed by construction or by an inability to staff them. There is also reputational and legal exposure: a July 2025 New York Times article on readmission rates at rehabilitation hospitals sent the stock down about 10 percent in a day and prompted several plaintiff law firms to announce securities investigations, and a separate ERISA class action over the company's retirement plan was filed in March 2026.

12 analysts publish price targets on EHC, averaging $148.17 against a $124.83 price as of August 2026, or +18.7%. The published targets run from $140.00 to $155.00, a narrow spread, and the ratings split 13 buy, 0 hold, 0 sell. Over the last six months there have been 4 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Encompass Health Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. De novo hospitals and bed additions. Growth here is physical, not promotional. The most optimistic published target, $155.00, assumes this works close to its best case.

The case against. Encompass is heavily dependent on a single payer whose rates are set by regulation, so any policy shift toward site-neutral payment between rehabilitation hospitals and skilled nursing facilities would hit the core economics directly, and MedPAC has argued for years that IRF margins are high. The most pessimistic target, $140.00, is roughly what EHC is worth if this bites instead.

Read the full bull and bear case on EHC, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Encompass Health Corporation's investor relations page or your broker.

• Revenue (TTM): ~$6.21B
• Q2 2026 revenue: ~$1.60B, up ~9.6%
• Q2 2026 adjusted EPS: ~$1.55
• FY2026 adjusted EBITDA guidance: ~$1.365B to $1.395B
• Market cap: ~$12.3B
• Forward P/E on 2026 guidance: ~20x

As of August 2026 the shares traded near $125, giving a market capitalization around $12.3 billion against trailing revenue of roughly $6.21 billion. Guided 2026 adjusted EPS of $6.02 to $6.25 puts the stock at about 20 times the midpoint, a premium to most hospital operators and a reflection of the visible bed pipeline rather than of any margin inflection. Second-quarter adjusted EBITDA margin was roughly 22 percent, and guidance was raised after the quarter rather than trimmed.

Other names that sit close to EHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get EHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so EHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

EHC is a steady Medicare business whose value rests on opening hospitals and adding beds faster than labor costs and reimbursement policy can erode the margin on them.

Whether EHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EHC a buy or a sell?, and where the stock could go from here in the EHC stock forecast.

For income investors, whether EHC pays a dividend and how the payout looks is covered in does EHC pay a dividend? And to weigh EHC against a peer, read the full side-by-side comparisons: EHC vs ADUS and EHC vs UNH.